Nephros (NASDAQ:NEPH) Releases Q1 2021 Earnings Guidance


Share on StockTwits

Nephros (NASDAQ:NEPH) issued an update on its first quarter 2021 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of – for the period. The company issued revenue guidance of $2.70 million-$2.70 million, compared to the consensus revenue estimate of $2.35 million.

Separately, B. Riley began coverage on Nephros in a report on Tuesday, January 26th. They set a buy rating and a $12.50 target price on the stock.

NASDAQ:NEPH traded down $0.09 during trading hours on Tuesday, reaching $7.90. 11,981 shares of the company traded hands, compared to its average volume of 16,110. The firm’s 50-day moving average is $7.54 and its 200-day moving average is $7.59. The stock has a market cap of $78.62 million, a P/E ratio of -17.17 and a beta of 0.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.94 and a quick ratio of 2.68. Nephros has a 1-year low of $5.08 and a 1-year high of $10.00.

Nephros (NASDAQ:NEPH) last announced its earnings results on Sunday, February 28th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. The firm had revenue of $2.33 million for the quarter, compared to analysts’ expectations of $2.29 million. Nephros had a negative return on equity of 36.33% and a negative net margin of 43.58%. As a group, research analysts predict that Nephros will post -0.56 earnings per share for the current year.

About Nephros

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Featured Story: Do closed-end mutual funds pay dividends?

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.